Brain Atrophy
Brain atrophy is the progressive loss of brain tissue — neurons and their connections — that occurs with aging and is accelerated by neurodegenerative diseases such as Alzheimer's.
What brain atrophy is
Brain atrophy refers to the loss of neurons and the connections between them (synapses and dendrites), resulting in reduction of brain volume. It can be generalized (affecting the brain broadly) or regional (concentrated in specific areas). Brain atrophy is measurable on MRI as increased prominence of sulci (the grooves on the brain surface), enlarged ventricles, and reduction in gray and white matter volume.
Some degree of brain atrophy is normal with aging. Average brain volume declines at approximately 0.2-0.5% per year in healthy adults over 60, accelerating in the 70s and 80s. The hippocampus shows somewhat faster age-related atrophy — approximately 0.5-1% per year in healthy older adults. This normal atrophy reflects neuronal loss, synaptic pruning, and changes in neuronal size and dendritic arborization.
Pathological atrophy — atrophy significantly exceeding normal aging — occurs in neurodegenerative diseases. In Alzheimer's disease, atrophy follows a characteristic pattern: the entorhinal cortex and hippocampus are affected first, followed by the medial temporal lobe broadly, then the posterior association cortex, and ultimately affecting most cortical regions. This pattern is exploited in MRI-based Alzheimer's biomarkers.
Why it matters for cognitive health
Regional brain atrophy correlates closely with cognitive function. Hippocampal volume loss correlates with episodic memory performance. Frontal lobe atrophy correlates with executive function and working memory. Posterior parietal atrophy correlates with visuospatial and attention performance. These correlations make MRI volumetrics a useful biomarker for tracking neurodegeneration and for clinical trial design.
Hippocampal atrophy rate, measurable over 6-12 months on serial MRI, is a validated biomarker for clinical trials of Alzheimer's treatments. It is also useful clinically — accelerated hippocampal atrophy in someone with memory complaints increases the probability of underlying Alzheimer's pathology, even before amyloid confirmation.
Factors that modify brain atrophy rate include cardiovascular risk management, sleep quality, and physical exercise — the same factors that modify cognitive aging more broadly. Aerobic exercise has been shown in clinical trials to slow or partially reverse hippocampal atrophy in older adults, providing direct structural evidence of neuroprotective effects.
Frequently asked questions
Can brain atrophy be reversed?
Most established atrophy in neurodegenerative disease cannot be reversed — lost neurons are not replaced in most brain regions. However, aerobic exercise has been shown to modestly increase hippocampal volume in older adults in controlled trials (Erickson et al., 2011), through effects on neurogenesis and dendritic arborization. The more practical goal is slowing atrophy rate rather than reversal, through cardiovascular risk management, sleep optimization, and exercise.
How is brain atrophy measured?
Brain atrophy is measured using MRI with specialized volumetric analysis software that parcels the brain into regions and measures each volume precisely. Serial MRI — comparing scans taken 6-12 months apart — allows measurement of atrophy rate. In clinical practice, a radiologist typically provides a qualitative judgment ('mild cortical volume loss consistent with age'); precise quantitative volumetrics are more common in research settings.
Related resources
Start tracking your cognitive baseline
Four minutes a day. Five short tests. One trend line that builds over weeks and months so you can see where you stand — and separate a bad day from a real change.
Free to start. No account required. Not a diagnostic tool.